Tag: Chinese plasma sector
CSL to buy majority stake in a leading Chinese plasma fractionator
Australian biotech firm CSL has agreed to acquire an 80% stake in China’s plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (Ruide) in...
Featured Article
Why energy is becoming a strategic asset for manufacturers
Energy is no longer just a cost centre for manufacturers – it is fast becoming a strategic lever for efficiency, resilience and growth.
